Are you sure you want to log out?
CBDin inflammatory bowel diseases: a brief overview
Cannabis finds its way into treatment of Crohn’s disease
CBDreduces intestinal inflammation through the control of neuroimmune axis
Cannabidiol, a safe and non-psychotropic ingredient of the marijuana plant Cannabis sativa, is protective in a murine model of colitis
The effects of Delta-tetrahydrocannabinol andCBD alone and in combination on damage, inflammation and in vitro motility disturbances in rat colitis
Topical and systemic cannabidiol improves trinitrobenzene sulfonic acid colitis in mice
Cannabinoids and the gut: New developments and emerging concepts
Endocannabinoids and the gastrointestinal tract
Cannabinoids and gastrointestinal motility: Animal and human studies
Hergenrather presents study of Crohn’s patients as a template for clinical research on Cannabis
Manipulation of the Endocannabinoid System in Colitis: A Comprehensive Review
Low-Dose Cannabidiol Is Safe but Not Effective in the Treatment for Crohn’s Disease, a Randomized Controlled Trial.
Cannabidiol in inflammatory bowel diseases: A brief overview
Clinical endocannabinoid deficiency (CECD): Can this concept explain therapeutic benefits of cannabis in migraine, fibromyalgia, irritable bowel syndrome and other treatment-resistant conditions?
Cannabinoid actions atTRPV channels: Effects on TRPV3 and TRPV4 and their potential relevance to gastrointestinal inflammation
Therapeutic potential of cannabinoid-based drugs
Beneficial effect of the non-psychotropic plant cannabinoid cannabigerol on experimental inflammatory bowel disease (Biochemical Pharmacology)
CBDand the gut: New developments and emerging concepts
CBDand gastrointestinal motility
Getting into the weed: the role of the endocannabinoid system in the brain-gut axis
1111 Brickell Avenue
Miami, FL 33131